NASDAQ:LPCN
Lipocine Inc.
Lipocine Inc.'s revenue fell 82.3% in fiscal 2025 to $2.0M while operating margin fell to −524.7%. The diluted share count rose 5.3%.Summary generated from Lipocine Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$2.0M
Revenue growth−82.3%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−524.7%
Net margin−487.1%
ROICn/a
Return on equity−54.3%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+5.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 16 | 1 | −3 | 11 | 2 |
| Operating income | 3 | −12 | −18 | −1 | −10 |
| Net income | −1 | −11 | −16 | 0 | −10 |
| Free cash flow | −4 | −12 | −12 | −1 | n/a |
Recent filings
- 8-KOther events
Oct 7, 2026 - 4Insider transaction report
Oct 1, 2026 - 4Insider transaction report
Sep 30, 2026 - 8-KOther events
Sep 16, 2026 - 8-KOther events
Sep 14, 2026 - 8-KOther events
Sep 11, 2026 - 8-KOther events
Sep 10, 2026 - 8-K/AAmended director or officer change
Aug 21, 2026